Sign in
Active, not recruitingNo phase

Effect of IOP Lowering on Progressive HM

Key facts

Who runs it
Sun Yat-sen University
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
152 people, planned
Started
1 Jun 2023
Expected to end
30 Nov 2028
Type of study
Interventional, 2 groupsOne group gets no study treatment, for comparison.
Treatments tested
  • Assigned Interventions: IOP-lowering eye drops
Record updated
5 November 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Informed consent given, and consent form signed
  • Age between 18 and 65 years
  • Diagnosed with HM: spherical equivalent ≤ -6.00 diopters or AL ≥ 26.5 mm
  • Progressive HM: progression in AL ≥0.05mm in the past 6 months or ≥0.1mm in the past 12 months
  • IOP ≥ 10 mmHg and ≤ 21mmHg on at least 2 visits, as measured by Goldmann applanation tonometry
  • Best corrected visual acuity (BCVA) ≥ 6/12, and being able to obtain adequate AL examination, fundus photographs, optical coherence tomography (OCT) and complete the VF examination

Who cannot take part

  • Patients who have undergone any surgery or laser treatment affecting eye parameters during the follow-up period (within the last 1 year), such as cataract surgery
  • Allergic to any kind of IOP-lowering therapy
  • Patients with other serious systemic diseases, such as hypertension, heart disease, diabetes, rheumatic immune system disease, etc., who cannot tolerate long-term follow-up and eye treatment
  • Combination of various serious fundus pathologies, such as proliferative diabetic retinopathy, retinal detachment, central retinal artery occlusion, etc
  • Combination of chronic, recurrent or severe ocular inflammatory lesions, such as chronic or recurrent uveitis
  • Patients with significant corneal or iris lesions, or severe cataract affecting fundus examination, or patients with only one eye
  • Pregnant or lactating women, or those who plan to have children during the follow-up period

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Currently, whether and when intraocular pressure (IOP) lowering medication should be used in progressive high myopia (HM) to control axial elongation is still a dilemma. Randomized trials are required to evaluate whether IOP lowering influences the growth of axial length in progressive HM eyes.

The 2 groups in the trial

  • Intervention armTreatment being tested

    medical reduction of IOP by eyedrops

    Treatment: Assigned Interventions: IOP-lowering eye drops

  • control armNo study treatment, for comparison

    follow up without medication

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effect of Medically Intraocular Pressure Lowering on Progressive High Myopia
Publications
Record updated
5 November 2026